Compare BioNano Genomics Inc (BNGO) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs McCormick & Company, Incorporated — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while McCormick & Company, Incorporated trades at $51.64 (market cap $14.21B). The key difference: McCormick & Company, Incorporated is far larger — about 1076.5× BioNano Genomics Inc's market cap, and McCormick & Company, Incorporated pays a 3.63% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MKC | |
|---|---|---|
Market Cap | $13.20M | $14.21B |
Sector | Health | Consumer Staples |
52-Week High | $4.92 | $72.81 |
52-Week Low | $1.09 | $45.60 |
Enterprise Value | $15.81M | $18.81B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
McCormick (MKC) trades at $53.75, up 2.48% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 21.91% net income margin and 25.7% ROE, while valuation metrics like a P/E of 8.94 appear attractive. Recent Q2 2026 earnings beat estimates, and the company reaffirmed its 2026 outlook, supported by the transformative Unilever Foods deal announced in July 2026.
Outlook is positive with a consensus price target of $59.67 offering 11% upside, driven by margin recovery and strategic acquisitions. Risks include soft consumer volumes in the Americas and integration challenges from the Unilever deal. The stock presents a value opportunity with a 4% dividend yield, but investors should monitor volume trends and deal execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
